BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vidri RJ, Vogt AO, Macgillivray DC, Bristol IJ, Fitzgerald TL. Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer. Ann Surg Oncol 2019;26:3701-8. [DOI: 10.1245/s10434-019-07584-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Barrak D, Villano AM, Villafane-Ferriol N, Stockton LG, Hill MV, Deng M, Handorf EA, Reddy SS. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Eur J Surg Oncol 2022:S0748-7983(21)01445-1. [PMID: 35016837 DOI: 10.1016/j.ejso.2021.12.473] [Reference Citation Analysis]
2 Zhao X, Cao D, Ren Z, Liu Z, Lv S, Zhu J, Li L, Lang R, He Q. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma. Biosci Rep 2020;40:BSR20200214. [PMID: 32701143 DOI: 10.1042/BSR20200214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vidri RJ, Olsen WT, Clark DE, Fitzgerald TL. Upfront resection versus neoadjuvant therapy for T1/T2 pancreatic cancer. HPB (Oxford) 2021;23:279-89. [PMID: 32698950 DOI: 10.1016/j.hpb.2020.06.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Laura A, Anna C, Cinquepalmi M, Giovanni M, Sole MM, Nava AK, Niccolò P, Giuseppe N, Stefano V, Paolo A, Francesco D, Giovanni R. Is Complete Pathologic Response in Pancreatic Cancer Overestimated? A Systematic Review of Prospective Studies. J Gastrointest Surg 2020;24:2336-48. [DOI: 10.1007/s11605-020-04697-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xie D, Qian B, Yang J, Peng X, Li Y, Hu T, Lu S, Chen X, Han Y. Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis. Front Oncol 2020;10:598048. [PMID: 33194764 DOI: 10.3389/fonc.2020.598048] [Reference Citation Analysis]
6 Kleeff J, Ronellenfitsch U, Michalski CW. Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? EClinicalMedicine 2019;17:100222. [PMID: 31891149 DOI: 10.1016/j.eclinm.2019.11.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Zhu X, Liu W, Cao Y, Su T, Zhu X, Wang Y, Ju X, Zhao X, Jiang L, Ye Y, Zhang H. Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Front Oncol 2021;11:688576. [PMID: 34169000 DOI: 10.3389/fonc.2021.688576] [Reference Citation Analysis]
8 Hue JJ, Dorth J, Sugumar K, Hardacre JM, Ammori JB, Rothermel LD, Saltzman J, Mohamed A, Selfridge JE, Bajor D, Winter JM, Ocuin LM. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era. Am Surg 2021;:31348211038581. [PMID: 34382877 DOI: 10.1177/00031348211038581] [Reference Citation Analysis]
9 Vidri RJ, Fitzgerald TL. GSK-3: An important kinase in colon and pancreatic cancers. Biochim Biophys Acta Mol Cell Res 2020;1867:118626. [PMID: 31987793 DOI: 10.1016/j.bbamcr.2019.118626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rebelo A, Büdeyri I, Heckler M, Partsakhashvili J, Ukkat J, Ronellenfitsch U, Michalski CW, Kleeff J. Systematic review and meta-analysis of contemporary pancreas surgery with arterial resection. Langenbecks Arch Surg 2020;405:903-19. [PMID: 32894339 DOI: 10.1007/s00423-020-01972-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]